- Continued development milestones following the 바카라사이트 정보 platform technology transfer in October 2024
- Additional milestones secured following initial target designation in March 2025
- Rising expectations for seamless clinical entry and commercialization of the 바카라사이트 정보 pipeline
[by Kang, In Hyo] 바카라사이트 정보 Biosciences (hereinafter referred to as 바카라사이트 정보 Bio) announced on January 8 that it is set to receive development milestone payments (stage-based royalties) from Ono Pharmaceutical for the previously executed technology transfer of its antibody-drug conjugate (ADC) platform.
The milestone payment follows the ADC platform technology transfer agreement executed in October 2024. At the time, LigaChem Bio and Ono Pharmaceutical committed inked the agreement to commit to the discovery and joint research of novel candidates utilizing LigaChem Bio's proprietary ADC platform, ‘ConjuAll.’
Immediately following the execution of the agreement, both parties achieved their first contractual milestone in March of last year with the successful selection of an initial target. The companies reported that R&D of the 바카라사이트 정보 candidate based on this target has progressed smoothly as originally planned, leading to this additional milestone payment.
While the specific amount and detailed terms of the milestone payment remain confidential under the terms of the agreement, this payment is widely viewed as validation of 바카라사이트 정보 Bio's ADC platform, reflecting its steady development progress and its ability to meet the high standards of leading global pharmaceutical companies.
"This milestone payment represents more than a one-off financial achievement, it reaffirms the strong foundation of trust established with Ono Pharmaceutical and underscores the exceptional scalability of our ADC platform technology," said Park Se-jin, COO & CFO of LigaChem Bio. "Receiving this news at the start of the new year demonstrates that our commitment to 'performance-driven R&D' is being executed as planned. By continuing to advance our pipeline and generate technology-based royalties, we aim to further enhance shareholder value and solidify our position as a leading global ADC company," he added.
On the other hand, 바카라사이트 정보 Bio is advancing multiple collaborations with a range of global partners, including Ono Pharmaceutical, and is on the verge of achieving additional milestones for other pipelines. Accordingly, expectations are increasing that the value of its ADC platform technology will be further validated, with development outcomes accelerating over the course of the year.